

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

HST Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when draft guidance issued)

- | |
|---|
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
| <p>No additional points were raised during consultation, but stakeholders reiterated that people with APDS from an ethnic minority background may have fewer suitable donors available for HSCT.</p> <p>The committee considered the issues raised at the first and second committee meeting. It noted that issues about challenges with diagnosis and management but were not able to address these within the appraisal. It did consider the impact the recommendation may have for people with protected characteristics (including race). It was aware that the use of hematopoietic stem cell transplants was very low in people with APDS aged 12 years and older. So it agreed that this was not a potential equality issue that could be addressed.</p> |
| 2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes. Please see section 3.20.

Approved by Associate Director (name): Lorna Dunning

Date: 19/02/25

